Cancer Biomarkers Market: Focus on TMB, MSI / MMR and TILs Testing, 2019–2030

WASHINGTON - Dec. 2, 2020 - PRLog -- The report features an extensive study of the current landscape and future outlook of the immuno-oncology biomarkers testing market (focusing particularly on TMB, MSI and TILs (CD3+, CD4+, CD8+, FOXP3+)). It provides an in-depth analysis, highlighting the capabilities of the various companies engaged in this domain. Amongst various elements, the report includes:

§  A detailed analysis of ongoing, biomarker-based clinical trials initiated by big pharmaceutical companies.

§  An analysis of the landscape of companies offering testing services for cancer biomarkers, namely TMB, MSI / MMR and TILs (including CD3+, CD4+, CD8+ and FOXP3+).

§  An insightful 2X2 representation of the results of a detailed competitiveness analysis of various tests (segregated across different biomarker groups).

§  Elaborate profiles of leading analytical testing service providers focused on immuno-oncology biomarkers (shortlisted based on strength of service portfolio).

§  A detailed publication analysis of over 180 research articles that have been published since 2016, highlighting the key focus areas of ongoing research activity related to immuno-oncology biomarkers, namely TMB, MSI / MMR and TILs.

§  A comprehensive clinical trial analysis of completed, ongoing and planned studies, focused on the assessment of cancer biomarkers, namely TMB, MSI / MMR and TILs.

§  A discussion on the upcoming opportunities that are likely to impact the evolution of this market over the coming years.

§  A discussion on various steps involved in development operations of companion diagnostics

§  A comparative analysis of the needs of different stakeholders involved in the development of companion diagnostic products

§  A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)

• Type of test

§  Laboratory Developed Tests (LDTs)

§  Companion Diagnostic Tests (CDx)

• Type of disease indication

§  Breast cancer

§  Blood cancer

§  Colon / Colorectal cancer

§  Lung Cancer

§  Melanoma

§  Prostate Cancer

• Type of cancer biomarker

§  TMB

§  MSI / MMR

§  TIL

For more information please click on the following link:

https://www.rootsanalysis.com/reports/view_document/cancer-biomarkers-market-focus-on-tmb-msi--mmr-and-tils-testing-2019--2030/253.html

Other Recent Offerings

1.      Global T-Cell (CAR-T, TCR, and TIL) Therapy Market (4th Edition), 2019-2030 (https://www.rootsanalysis.com/reports/view_document/globa...)

2.      Neoantigen Targeted Therapies Market, 2019-2030

3.      Companion Diagnostics Market (2nd Edition), 2019-2030

4.      Cell Encapsulation: Focus on Therapeutics and Technologies, 2019-2030

5.      In Vitro ADME Testing Services Market, 2019-2030

Contact Information

Roots Analysis Private Limited

Gaurav Chaudhary

+1 (415) 800 3415

gaurav.chaudhary@rootsanalysis.com